Prot #BH-30236-01: A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults

Project: Research project

Project Details

StatusActive
Effective start/end date5/28/25 → 5/28/28

Funding

  • Pharmaceutical Research Associates, Inc. (Prot #BH-30236-01 // Prot #BH-30236-01)
  • BlossomHill Therapeutics, Inc. (Prot #BH-30236-01 // Prot #BH-30236-01)